Retroviral vectors for HIV immunotherapy.
Viagene, Inc., San Diego, California 92121, USA.
J F
JF
Warner
D
D
Jolly
S
S
Mento
J
J
Galpin
R
R
Haubrich
J
J
Merritt
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002478:Cells, Cultured; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology*; D015694:Gene Products, rev / Q000235:genetics / Q000276:immunology*; D015316:Genetic Therapy / Q000009:adverse effects; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000096:biosynthesis*; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active / Q000009:adverse effects; D007273:Injections, Intramuscular; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010215:Papio; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D012190:Retroviridae / Q000235:genetics*; D012449:Safety; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D054321:rev Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015686:Gene Products, env; D015694:Gene Products, rev; D015483:HIV Antibodies; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D054321:rev Gene Products, Human Immunodeficiency Virus